Navigation Links
ViroPharma to Present at the BIO CEO & Investor Conference
Date:2/5/2008

EXTON, Pa., Feb. 5 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, chief financial officer and chief operating officer of ViroPharma, will present at the BIO CEO & Investor Conference at 12:30 P.M. ET on Monday, February 11, 2008. The conference is being held at the Waldorf=Astoria, in New York.

ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through February 28, 2008.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...k investment bank KTA Capital,s client Neuren Phar... convertible note private placement with a U.S. in...ranged by KTA Capital as Neuren,s exclusive placem...New York (PRWEB) November 23, 2009 -- The independ...ot;KTA Capital") has announced that its clien...
(Date:11/24/2009)...Newswire-FirstCall/ -- Sigma-Aldrich Corporation (...MX conference on Tuesday, December 1st at 1:45 PM ...may listen via live audio broadcast over the Inter...a ldrich.com/ . Users can click the "Webcast" i...rich: Sigma-Aldrich is a leading Life Science an...
(Date:11/24/2009)...v. 24 NeurogesX, Inc. (N...d on developing and commercializing novel pain man...Tonno, President and Chief Executive Officer, is s...ay Health Care Conference, to be held December 1-2...ew York. ,, Mr. DiTonno and Stephen Ghiglieri,...
(Date:11/24/2009)...dpoint has been met for patients with advanced-sta...BEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna...mpany"), a global biopharmaceutical company focuse...ed positive efficacy data from a Phase 2 study wit...08 (formerly AN-152), in patients with advanced or...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...nology Network , Gov. Jim Doyle wrote about the ...ng our state,s economy. The governor missed the ma... of the best in the country. In order to remain on...ate and evolve, something it has done little of si... Board of Regents have shown they are not open to...
...s reached an agreement to install clinical informa..., a Milwaukee-based medical informatics company. ,... to integrate all of Marshfield,s clinical data, i...ribute them within the clinic,s electronic medical...field Clinic,s healthcare professionals through In...
...his life-science company, GenTel BioSciences , ha...tein chip platform from GlaxoSmithKline , but jus...e technology improves the quality of data GenTel d...ped a protein chip used by cancer researchers, ann... new facility in the Fitchburg Technology Campus ...
Other Biology Technology:UW System must remove barriers to innovation 2UW System must remove barriers to innovation 3UW System must remove barriers to innovation 4GenTel acquires GlaxoSmithKline chip platform 2GenTel acquires GlaxoSmithKline chip platform 3
(Date:11/25/2009)... assistant professors recently received funding fr...ue research beneficial to understanding the enviro...opher Blackwood, assistant professor in the Depart... support two separate research projects. , His f... Communities and Functions from the Leaf to the La...
(Date:11/24/2009)...sed a protein that may help gut bacteria bind to t...ed by probiotic producers to identify strains that...robiotics need to interact with cells lining the g... to surfaces in the gut they are more likely to st...ays Dr Nathalie Juge from the Institute of Food Re...
(Date:11/24/2009)... has long held secrets of the earth,s history lock...s been very little information on the environments...llions of years. Now, a team of researchers from n...to the tune of $10 million dollars by the National...of things literally. These scientists will drill ...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2Immune Response May Speed AIDS Progression in Women 51503 1Immune Response May Speed AIDS Progression in Women 51503 2Moderate Drinking Might Guard Against Alzheimers 51501 1Moderate Drinking Might Guard Against Alzheimers 51501 2Moderate Drinking Might Guard Against Alzheimers 51501 3Moderate Drinking Might Guard Against Alzheimers 51501 4Researchers gain insight into mechanism underlying Huntingtons 9240 1Researchers gain insight into mechanism underlying Huntingtons 9240 2
...have suspected that the three known domains of lif... off and went their separate ways around three bil...split has been an elusive task. , Now, a team of ...domains of life coexisted at least as long as 2.7 ...ical examination of shale samples, loaded with oil...
...ttle coal and processing the papermaking industry,...r choice than burning it for heat, improves the ca...n produce a fuel versatile enough to run a cooking...te engineers., "Black liquor is routinely burned ...or of fuel science. "But it has more energy value ...
...f end products including jet fuel, gasoline, carbo...sting refineries and combinations of coal and refi...e researchers., "One idea is based on the coal-to...time," says Caroline E. Burgess Clifford, research...aim is to integrate the processes and products int...
Other Biology News:Ancient organisms discovered in Canadian gold mine 2Coal and black liquor can produce energy from papermaking 2Coal-based fuels and products hit the refinery 2
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-GPCR G2A Polyclonal Antibody, Unconjugated from Abcam
Anti-6-keto Prostaglandin F1 alpha (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems
Biology Products: